A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

NCT ID: NCT05068284

Last Updated: 2024-10-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2023-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active CD. Adverse events and change in the disease activity will be assessed.

ABBV-154 is an investigational drug being evaluated for the treatment of CD. In the induction period, there is a 1 in 5 chance that participants will be assigned to placebo. Depending on the dose received in the induction period, there is a 1 in 2 or 1 in 3 chance that participants will be assigned to placebo in the maintenance period. Around 265 participants 18-75 years of age with moderately to severely active CD will be enrolled in the study at approximately 200 sites worldwide.

The study is comprised of a 12-week double-blind, placebo-controlled induction period, followed by either a 12-week double-blind re-induction period for non-responders or a 40-week double-blind placebo-controlled maintenance period for responders. In the maintenance period, responders will be randomized to receive subcutaneous placebo or ABBV-154 in 2 different doses every other week. Participants in the placebo group who are initial responders will receive ABBV-154 in the maintenance period.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Induction Phase: ABBV-154 Randomized Dose A

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Induction Phase: ABBV-154 Randomized Dose B

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Induction Phase: ABBV-154 Randomized Dose C

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Induction Phase: ABBV-154 Randomized Dose D

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Placebo

Intervention Type DRUG

Subcutaneous Injection

Induction Phase: Randomized Placebo

Fixed dose placebo as described in the protocol.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intravenous (IV) infusion; Subcutaneous Injection

Re-Induction Phase: ABBV-154 Randomized Dose A

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Re-Induction Phase: ABBV-154 Randomized Dose B

Varying doses of ABBV-154 as described in the protocol.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Intravenous (IV) Infusion; Subcutaneous Injection

Maintenance Phase: ABBV-154 Randomized Dose A

Fixed dose ABBV-154 every other week.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Subcutaneous Injection

Maintenance Phase: ABBV-154 Randomized Dose B

Fixed dose ABBV-154 every other week.

Group Type EXPERIMENTAL

ABBV-154

Intervention Type DRUG

Subcutaneous Injection

Maintenance Phase: Randomized Placebo

Fixed dose placebo every other week.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Subcutaneous Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABBV-154

Intravenous (IV) Infusion; Subcutaneous Injection

Intervention Type DRUG

Placebo

Intravenous (IV) infusion; Subcutaneous Injection

Intervention Type DRUG

ABBV-154

Subcutaneous Injection

Intervention Type DRUG

Placebo

Subcutaneous Injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of Crohn's Disease (CD) for at least 3 months prior to Baseline of the Induction Period.
* Crohn's Disease Activity Index (CDAI) score 220 to 450 at Baseline of the Induction Period.
* Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of \>= 6 for ileocolonic or colonic disease or SES-CD of \>= 4 for isolated ileal disease as scored by a central reader. All eligible scores must exclude the presence of narrowing component.
* Demonstrated intolerance or inadequate response to one or more of the following biologic agents: infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, ustekinumab, or risankizumab.

Exclusion Criteria

\- Participants with prior intolerance to adalimumab.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Digestive Health Specialists of the Southeast /ID# 239599

Dothan, Alabama, United States

Site Status

East View Medical Research, LLC /ID# 240030

Mobile, Alabama, United States

Site Status

Southern California Res. Ctr. /ID# 233512

Coronado, California, United States

Site Status

Hoag Memorial Hosp Presbyterian /ID# 233555

Irvine, California, United States

Site Status

University of Colorado Hospital /ID# 239361

Aurora, Colorado, United States

Site Status

Medical Research Center of CT /ID# 233542

Hamden, Connecticut, United States

Site Status

Atlantic Medical Research /ID# 233506

Margate, Florida, United States

Site Status

University of Miami /ID# 233811

Miami, Florida, United States

Site Status

Gastroenterology Group Naples /ID# 233829

Naples, Florida, United States

Site Status

Digestive Disease Consultants - Orange Park /ID# 241015

Orange Park, Florida, United States

Site Status

Endoscopic Research, Inc. /ID# 234279

Orlando, Florida, United States

Site Status

IMIC Inc. Medical Research /ID# 233821

Palmetto Bay, Florida, United States

Site Status

Emory University /ID# 241014

Atlanta, Georgia, United States

Site Status

AGILE Clinical Research Trials /ID# 233739

Atlanta, Georgia, United States

Site Status

Gastroenterology Associates of Central Georgia, LLC /ID# 245604

Macon, Georgia, United States

Site Status

GI Specialists of GA, PC /ID# 239261

Marietta, Georgia, United States

Site Status

Gastroenterology Consultants, P.C /ID# 233552

Roswell, Georgia, United States

Site Status

The University of Chicago DCAM /ID# 233824

Chicago, Illinois, United States

Site Status

Digestive Health Services /ID# 241177

Downers Grove, Illinois, United States

Site Status

Southwest Gastroenterology /ID# 234278

Oak Lawn, Illinois, United States

Site Status

University of Louisville /ID# 233766

Louisville, Kentucky, United States

Site Status

Louisiana Research Center, LLC /ID# 245370

Shreveport, Louisiana, United States

Site Status

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 233765

Ann Arbor, Michigan, United States

Site Status

Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 233763

Wyoming, Michigan, United States

Site Status

Mayo Clinic - Rochester /ID# 238516

Rochester, Minnesota, United States

Site Status

Las Vegas Medical Research /ID# 233826

Las Vegas, Nevada, United States

Site Status

Allied Health Clinical Research Organization, LLC /ID# 241935

Englewood, New Jersey, United States

Site Status

The Mount Sinai Hospital /ID# 233823

New York, New York, United States

Site Status

Lenox Hill Hospital /ID# 239312

New York, New York, United States

Site Status

New York Gastroenterology Associates /ID# 241967

New York, New York, United States

Site Status

Univ NC Chapel Hill /ID# 233557

Chapel Hill, North Carolina, United States

Site Status

Northshore Gastroentrology Research LLC /ID# 239307

Brooklyn, Ohio, United States

Site Status

University of Cincinnati /ID# 234237

Cincinnati, Ohio, United States

Site Status

Hightower Clinical /ID# 239598

Oklahoma City, Oklahoma, United States

Site Status

Digestive Disease Specialists /ID# 233825

Oklahoma City, Oklahoma, United States

Site Status

University of Pennsylvania /ID# 239291

Philadelphia, Pennsylvania, United States

Site Status

Allegheny Health Network Research Institute /ID# 239334

Pittsburgh, Pennsylvania, United States

Site Status

Gastroenterology Associates, P.A. of Greenville /ID# 233544

Greenville, South Carolina, United States

Site Status

Gastro One /ID# 239748

Cordova, Tennessee, United States

Site Status

Southern Star Research Institute, LLC /ID# 240132

San Antonio, Texas, United States

Site Status

Tyler Research Institute, LLC /ID# 233730

Tyler, Texas, United States

Site Status

Gastro Health & Nutrition - Victoria /ID# 240158

Victoria, Texas, United States

Site Status

University of Utah Hospitals and Clinics /ID# 239264

Salt Lake City, Utah, United States

Site Status

Gastro Health Research /ID# 240085

Fairfax, Virginia, United States

Site Status

Hunter Holmes McGuire VA Medical Center /ID# 233759

Richmond, Virginia, United States

Site Status

Concord Repatriation General /ID# 233467

Concord, New South Wales, Australia

Site Status

Princess Alexandra Hospital /ID# 234243

Woolloongabba, Queensland, Australia

Site Status

Royal Adelaide Hospital /ID# 233705

Adelaide, South Australia, Australia

Site Status

The Queen Elizabeth Hospital /ID# 234242

Woodville South, South Australia, Australia

Site Status

Monash Medical Centre /ID# 233469

Clayton, Victoria, Australia

Site Status

Fiona Stanley Hospital /ID# 240136

Murdoch, Western Australia, Australia

Site Status

Medizinische Universitaet Innsbruck /ID# 234217

Innsbruck, Tyrol, Austria

Site Status

Medizinische Universitaet Wien /ID# 234218

Vienna, Vienna, Austria

Site Status

Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 234069

Salzburg, , Austria

Site Status

UCL Saint-Luc /ID# 232435

Woluwe-Saint-Lambert, Brussels Capital, Belgium

Site Status

UZ Gent /ID# 246877

Ghent, Oost-Vlaanderen, Belgium

Site Status

AZ-Delta /ID# 232437

Roeselare, West-Vlaanderen, Belgium

Site Status

AZ Maria Middelares /ID# 246880

Ghent, , Belgium

Site Status

CHU de Liege /ID# 232436

Liège, , Belgium

Site Status

UMHAT Kaspela /ID# 232468

Plovdiv, , Bulgaria

Site Status

Second MHAT Sofia /ID# 250706

Sofia, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski /ID# 233522

Sofia, , Bulgaria

Site Status

UMHAT Tsaritsa Joanna - ISUL /ID# 234135

Sofia, , Bulgaria

Site Status

Acibadem City Clinic University Hospital EOOD /ID# 240003

Sofia, , Bulgaria

Site Status

University of Calgary /ID# 233838

Calgary, Alberta, Canada

Site Status

Gastroenterology and Internal Medicine Research Institution /ID# 233831

Edmonton, Alberta, Canada

Site Status

QE II Health Sciences Centre /ID# 233839

Halifax, Nova Scotia, Canada

Site Status

London Health Sciences Center- University Hospital /ID# 234058

London, Ontario, Canada

Site Status

Scott Shulman Medicine Professional Corporation /ID# 239567

North Bay, Ontario, Canada

Site Status

Toronto Immune and Digestive Health Institute Inc /ID# 234142

North York, Ontario, Canada

Site Status

Toronto Digestive Disease Associates, Inc. /ID# 234143

Vaughan, Ontario, Canada

Site Status

Hepato-Gastroenterologie HK, s.r.o. /ID# 239965

Hradec Králové, , Czechia

Site Status

ARTROSCAN s.r.o. /ID# 239882

Ostrava, , Czechia

Site Status

Nemocnice Horovice - NH Hospital a.s /ID# 233915

Prague, , Czechia

Site Status

Ustredni Vojenska Nemocnice - Vojenska fakultni nemocnice Praha /ID# 238486

Prague, , Czechia

Site Status

CHU Montpellier - Hôpital Saint Eloi /ID# 241136

Montpellier, Herault, France

Site Status

CHRU Nancy - Hopitaux de Brabois /ID# 234224

Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

Site Status

CHU de SAINT ETIENNE - Hopital Nord /ID# 234225

Saint Priest EN Jarez, Pays de la Loire Region, France

Site Status

AP-HP - Hopital Saint-Louis /ID# 234227

Paris, , France

Site Status

Universitaetsklinikum Freiburg /ID# 233719

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

Universitatsklinikum Mannheim /ID# 233716

Mannheim, Baden-Wurttemberg, Germany

Site Status

Universitaetsklinikum Ulm /ID# 233531

Ulm, Baden-Wurttemberg, Germany

Site Status

Universitaetsklinikum Erlangen /ID# 233529

Erlangen, Bavaria, Germany

Site Status

Universitatsklinik Regensburg /ID# 238702

Regensburg, Bavaria, Germany

Site Status

Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 233527

Kiel, Schleswig-Holstein, Germany

Site Status

DRK Kliniken Berlin Westend /ID# 233718

Berlin, , Germany

Site Status

Medizinische Hochschule Hannover /ID# 238804

Hanover, , Germany

Site Status

EUGASTRO GmbH /ID# 233717

Leipzig, , Germany

Site Status

Klinikum Lueneburg /ID# 233720

Lüneburg, , Germany

Site Status

General Hospital of Athens Ippokratio /ID# 231655

Athens, Attica, Greece

Site Status

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 231660

Athens, Attica, Greece

Site Status

University General Hospital of Heraklion PA.G.N.I /ID# 231657

Heraklion, Crete, Greece

Site Status

General Hospital of Nikaia-Piraeus "Agios Panteleimon" /ID# 231659

Pireaus, , Greece

Site Status

Clinfan Szolgaltato Kft. /ID# 249662

Szekszárd, , Hungary

Site Status

Shaare Zedek Medical Center /ID# 233460

Jerusalem, Jerusalem, Israel

Site Status

Hadassah Medical Center-Hebrew University /ID# 233518

Jerusalem, Jerusalem, Israel

Site Status

The Edith Wolfson Medical Center /ID# 234042

Ashkelon, Southern District, Israel

Site Status

Soroka University Medical Center /ID# 233458

Beersheba, Southern District, Israel

Site Status

The Chaim Sheba Medical Center /ID# 233457

Ramat Gan, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 238525

Tel Aviv, Tel Aviv, Israel

Site Status

ASST Rhodense/Presidio Ospedaliero di Rho /ID# 233386

Rho, Milano, Italy

Site Status

Policlinico Agostino Gemelli /ID# 233380

Rome, Roma, Italy

Site Status

Azienda Ospedaliera Universitaria Consorziale Policlinico /ID# 233387

Bari, , Italy

Site Status

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 233382

Milan, , Italy

Site Status

Aichi Medical University Hospital /ID# 238528

Nagakute-shi, Aichi-ken, Japan

Site Status

Daido Clinic /ID# 239730

Nagoya, Aichi-ken, Japan

Site Status

Nagoya University Hospital /ID# 238662

Nagoya, Aichi-ken, Japan

Site Status

Nagoya City University Hospital /ID# 238368

Nagoya, Aichi-ken, Japan

Site Status

Tsujinaka Hospital Kashiwanoha /ID# 239012

Kashiwa-shi, Chiba, Japan

Site Status

Fukushima Medical University Hospital /ID# 239314

Fukushima, Fukushima, Japan

Site Status

Gunma University Hospital /ID# 239913

Maebashi, Gunma, Japan

Site Status

Hiroshima University Hospital /ID# 238947

Hiroshima, Hiroshima, Japan

Site Status

Asahikawa City Hospital /ID# 248061

Asahikawa-shi, Hokkaido, Japan

Site Status

Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 238791

Sapporo, Hokkaido, Japan

Site Status

Sapporo Medical University Hospital /ID# 239201

Sapporo, Hokkaido, Japan

Site Status

Sapporo IBD Clinic /ID# 239054

Sapporo, Hokkaido, Japan

Site Status

Hyogo Medical University Hospital /ID# 239049

Nishinomiya-shi, Hyōgo, Japan

Site Status

Kanazawa University Hospital /ID# 239670

Kanazawa, Ishikawa-ken, Japan

Site Status

Iwate Medical University Uchimaru Medical Center /ID# 238953

Morioka, Iwate, Japan

Site Status

St. Marianna University Hospital /ID# 239167

Kawasaki-shi, Kanagawa, Japan

Site Status

University Hospital Kyoto Prefectural University of Medicine /ID# 239918

Kyoto, Kyoto, Japan

Site Status

Mie University Hospital /ID# 239758

Tsu, Mie-ken, Japan

Site Status

Tohoku University Hospital /ID# 238476

Sendai, Miyagi, Japan

Site Status

Okayama University Hospital /ID# 239757

Okayama, Okayama-ken, Japan

Site Status

Osaka Metropolitan University Hospital /ID# 238638

Osaka, Osaka, Japan

Site Status

Osaka University Hospital /ID# 240485

Suita-shi, Osaka, Japan

Site Status

Hamamatsu University Hospital /ID# 238527

Hamamatsu, Shizuoka, Japan

Site Status

NHO Shizuoka Medical Center /ID# 239759

Sunto-gun, Shizuoka, Japan

Site Status

Tokyo Medical And Dental University Hospital /ID# 238950

Bunkyo-ku, Tokyo, Japan

Site Status

Kyorin University Hospital /ID# 239609

Mitaka-shi, Tokyo, Japan

Site Status

Tokyo Medical University Hospital /ID# 239668

Shinjuku-ku, Tokyo, Japan

Site Status

Center hospital of the National Center for Global Health and Medicine /ID# 239792

Shinjuku-ku, Tokyo, Japan

Site Status

Tokyo Women's Medical University Hospital /ID# 239760

Shinjuku-ku, Tokyo, Japan

Site Status

Japan Community Health care Organization Tokyo Yamate Medical Center /ID# 239554

Shinjuku-ku, Tokyo, Japan

Site Status

Yamagata University Hospital /ID# 239572

Yamagata, Yamagata, Japan

Site Status

Radboud Universitair Medisch Centrum /ID# 241292

Nijmegen, Gelderland, Netherlands

Site Status

Academisch Medisch Centrum /ID# 232123

Amsterdam, , Netherlands

Site Status

Dunedin Hospital /ID# 238325

Otago, Otago, New Zealand

Site Status

Wellington Regional Hospital /ID# 238326

Newtown, Wellington Region, New Zealand

Site Status

Hutt Hospital /ID# 238327

Lower Hutt, , New Zealand

Site Status

Planetmed Sp. z o.o. /ID# 238447

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

WIP Warsaw IBD Point Profesor Kierkus /ID# 233533

Warsaw, Masovian Voivodeship, Poland

Site Status

Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 238653

Warsaw, Masovian Voivodeship, Poland

Site Status

Endoskopia Sp. z o.o. /ID# 249906

Sopot, Pomeranian Voivodeship, Poland

Site Status

Hospital da Senhora da Oliveira Guimaraes, EPE /ID# 249047

Guimarães, Braga District, Portugal

Site Status

2CA-Braga, Hospital de Braga /ID# 249049

Braga, , Portugal

Site Status

Mindful Medical Research /ID# 249609

San Juan, , Puerto Rico

Site Status

Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 232373

Banská Bystrica, , Slovakia

Site Status

ENDOMED s.r.o. /ID# 241855

Košice, , Slovakia

Site Status

KM Management, spol. s.r.o. /ID# 241849

Nitra, , Slovakia

Site Status

The Catholic University of Korea, Daejeon St.Mary's Hospital /ID# 233700

Daejeon, , South Korea

Site Status

Asan Medical Center /ID# 233701

Seoul, , South Korea

Site Status

Samsung Medical Center /ID# 233698

Seoul, , South Korea

Site Status

Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 232299

Ferrol, A Coruna, Spain

Site Status

Hospital Santa Creu i Sant Pau /ID# 232301

Barcelona, , Spain

Site Status

Hospital Universitario La Paz /ID# 232300

Madrid, , Spain

Site Status

Hospital Clinico Universitario de Valencia /ID# 234103

Valencia, , Spain

Site Status

China Medical University Hospital /ID# 234132

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital /ID# 234131

Taichung, , Taiwan

Site Status

National Taiwan University Hospital /ID# 234134

Taipei, , Taiwan

Site Status

Royal Devon University Healthcare NHS Foundation Trust /ID# 234194

Exeter, Devon, United Kingdom

Site Status

University Hospital Southampton NHS Foundation Trust /ID# 238960

Southampton, Hampshire, United Kingdom

Site Status

Barts Health NHS Trust /ID# 234188

London, London, City of, United Kingdom

Site Status

Guys and St Thomas NHS Foundation Trust /ID# 234191

London, London, City of, United Kingdom

Site Status

NHS Greater Glasgow and Clyde /ID# 234186

Glasgow, Scotland, United Kingdom

Site Status

St George's University Hospitals NHS Foundation Trust /ID# 234193

Tooting, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Czechia France Germany Greece Hungary Israel Italy Japan Netherlands New Zealand Poland Portugal Puerto Rico Slovakia South Korea Spain Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-002869-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M20-371

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.